Ocular immune privilege and ocular melanoma: parallel universes or immunological plagiarism?
- PMID: 22707951
- PMCID: PMC3374415
- DOI: 10.3389/fimmu.2012.00148
Ocular immune privilege and ocular melanoma: parallel universes or immunological plagiarism?
Abstract
Evidence of immune privilege in the eye was recorded almost 140 years ago, yet interest in immune privilege languished for almost a century. However, the past 35 years have witnessed a plethora of research and a rekindled interest in the mechanisms responsible for immune privilege in the anterior chamber of the eye. This research has demonstrated that multiple anatomical, structural, physiological, and immunoregulatory processes contribute to immune privilege and remind us of the enormous complexity of this phenomenon. It is widely accepted that immune privilege is an adaptation for reducing the risk of immune-mediated inflammation in organs such as the eye and brain whose tissues have a limited capacity to regenerate. Recent findings suggest that immune privilege also occurs in sites where stem cells reside and raise the possibility that immune privilege is also designed to prevent the unwitting elimination of stem cells by immune-mediated inflammation at these sites. Uveal melanoma arises within the eye and as such, benefits from ocular immune privilege. A significant body of research reveals an intriguing parallel between the mechanisms that contribute to immune privilege in the eye and those strategies used by uveal melanoma cells to evade immune elimination once they have disseminated from the eye and establish metastatic foci in the liver. Uveal melanoma metastases seem to have "plagiarized" the blueprints used for ocular immune privilege to create "ad hoc immune privileged sites" in the liver.
Keywords: anterior chamber; eye; immune privilege; stem cells; uveal melanoma.
Figures

Similar articles
-
Immune escape mechanisms of intraocular tumors.Prog Retin Eye Res. 2009 Sep;28(5):329-47. doi: 10.1016/j.preteyeres.2009.06.002. Epub 2009 Jun 27. Prog Retin Eye Res. 2009. PMID: 19563908 Free PMC article. Review.
-
Immune privilege in the anterior chamber of the eye.Crit Rev Immunol. 2002;22(1):13-46. Crit Rev Immunol. 2002. PMID: 12186187 Review.
-
History and physiology of immune privilege.Ocul Immunol Inflamm. 2010 Jan;18(1):19-23. doi: 10.3109/09273940903564766. Ocul Immunol Inflamm. 2010. PMID: 20128645
-
Mechanisms of immune privilege in the anterior segment of the eye: what we learn from corneal transplantation.J Ocul Biol Dis Infor. 2008 Dec;1(2-4):94-100. doi: 10.1007/s12177-008-9010-6. Epub 2008 Aug 8. J Ocul Biol Dis Infor. 2008. PMID: 20072639 Free PMC article.
-
Immune privilege of the eye and fetus: parallel universes?Transplantation. 2005 Nov 15;80(9):1139-44. doi: 10.1097/01.tp.0000173828.78382.4f. Transplantation. 2005. PMID: 16314777 Review.
Cited by
-
The anterior chamber of the eye technology and its anatomical, optical, and immunological bases.Physiol Rev. 2024 Jul 1;104(3):881-929. doi: 10.1152/physrev.00024.2023. Epub 2024 Jan 11. Physiol Rev. 2024. PMID: 38206586 Free PMC article. Review.
-
Construction of a Promising Tumor-Infiltrating CD8+ T Cells Gene Signature to Improve Prediction of the Prognosis and Immune Response of Uveal Melanoma.Front Cell Dev Biol. 2021 May 28;9:673838. doi: 10.3389/fcell.2021.673838. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34124058 Free PMC article.
-
Role of Natural Killer Cells in Uveal Melanoma.Cancers (Basel). 2020 Dec 9;12(12):3694. doi: 10.3390/cancers12123694. Cancers (Basel). 2020. PMID: 33317028 Free PMC article. Review.
-
Landscape of Infiltrated Immune Cell Characterization in Uveal Melanoma to Improve Immune Checkpoint Blockade Therapy.Front Immunol. 2022 Mar 2;13:848455. doi: 10.3389/fimmu.2022.848455. eCollection 2022. Front Immunol. 2022. PMID: 35309331 Free PMC article.
-
Differential modulation and prognostic values of immune-escape genes in uveal melanoma.PLoS One. 2019 Jan 17;14(1):e0210276. doi: 10.1371/journal.pone.0210276. eCollection 2019. PLoS One. 2019. PMID: 30653520 Free PMC article.
References
-
- Apte R. S., Mayhew E., Niederkorn J. Y. (1997). Local inhibition of natural killer cell activity promotes the progressive growth of intraocular tumors. Invest. Ophthalmol. Vis. Sci. 38, 1277–1282 - PubMed
-
- Apte R. S., Niederkorn J. Y. (1996). Isolation and characterization of a unique natural killer cell inhibitory factor present in the anterior chamber of the eye. J. Immunol. 156, 2667–2673 - PubMed
-
- Apte R. S., Sinha D., Mayhew E., Wistow G. J., Niederkorn J. Y. (1998). Cutting edge: role of macrophage migration inhibitory factor in inhibiting NK cell activity and preserving immune privilege. J. Immunol. 160, 5693–5696 - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous